ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 9, 2007--Emergent
BioSolutions Inc. (NYSE: EBS) announced today that Ms. Denise Landry
has joined the company as Senior Vice President, Quality with
responsibility for managing and overseeing all Quality activities
company-wide. Ms. Landry has broad-based quality experience for
pharmaceutical and biologics operations, including activities relating
to all phases of product development, regulatory submissions, and
compliance programs. In addition, Mrs. Landry has extensive experience
interacting with regulatory authorities including the U.S. Food and
Drug Administration (FDA), the European Medicines Agency (EMEA) and
the Medicines and Healthcare Product Regulatory Agency (MHRA) in the
Fuad El-Hibri, chairman and chief executive officer of Emergent
BioSolutions stated "I am pleased to welcome Ms. Denise Landry to
Emergent BioSolutions as Senior Vice-President, Quality. Her two
decades of experience in the Quality programs will be a critical asset
to our team. Denise's first-hand experience and breadth of knowledge
make her uniquely qualified for such an important role in our
Ms. Landry joins the company from MGI Pharma Inc. and its
predecessor Guilford Pharmaceuticals, where she served as Vice
President, Corporate Quality. Prior to her 13 year tenure there, Ms.
Landry was the Director Quality Assurance for Pharmaceutical Systems,
Inc. and Quality Assurance Director for Smith & Nephew Solopak. She
began her career in the quality control field as a Service Quality
Manager for Baxter Healthcare Corporation.
"I am very pleased to be joining the management team at Emergent
BioSolutions, and I share their commitment to maintaining the highest
quality standards in manufacturing and product development," said Ms.
Denise Landry. "I have dedicated my career to this industry and look
forward to leading and promoting continuous quality improvement
throughout the company as it develops and manufactures products to
Mrs. Landry holds a BA in Biology from Fisk University in
Tennessee. She is a member of the American Society of Quality Control
and the Parenteral Drug Association.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company
dedicated to one simple mission--to protect life. We develop,
manufacture and commercialize immunobiotics, consisting of vaccines
and therapeutics that assist the body's immune system to prevent or
treat disease. Our biodefense business focuses on immunobiotics for
use against biological agents that are potential weapons of
bioterrorism and biowarfare. Our marketed product, BioThrax(R)
(Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S.
Food and Drug Administration for the prevention of anthrax disease.
Our commercial business focuses on immunobiotics for use against
infectious diseases and other medical conditions that have resulted in
significant unmet or underserved public health needs. More information
on the company is available at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, including any statements containing the
words "believes", "expects", "anticipates", "plans", "estimates" and
similar expressions, are forward-looking statements. There are a
number of important factors that could cause the company's actual
results to differ materially from those indicated by such
forward-looking statements, including the execution of our strategy by
our executive team; our plans to expand our manufacturing facilities
and capabilities; the rate and degree of market acceptance and
clinical utility of our products; our ongoing and planned development
programs, preclinical studies and clinical trials; our ability to
identify and acquire or in license products and product candidates
that satisfy our selection criteria; the potential benefits of our
existing collaboration agreements and our ability to enter into
selective additional collaboration arrangements; the timing of and our
ability to obtain and maintain regulatory approvals for our product
candidates; our commercialization, marketing and manufacturing
capabilities and strategy; our intellectual property portfolio; and
other factors identified in the company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2007 and subsequent reports filed
with the SEC. The company disclaims any intention or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this press release.
CONTACT: Investors Contact:
Emergent BioSolutions Inc.
Robert G. Burrows, Vice President, Investor Relations
Tracey Schmitt, Director, Corporate Communications
SOURCE: Emergent BioSolutions Inc.